Article | January 12, 2023

Being Prepared: Business Continuity Planning In The Life Science Industry

By Sinead McGlone, Director, Quality, IQVIA

Medical Science BioProcess

Business continuity planning (BCP) ahead of the next pandemic or natural disaster is essential to ensure the success of any enterprise, but it's particularly crucial for companies in the life science industry. A sound BCP gives companies a roadmap and processes to follow in times of crisis. The plans outline what the company must do to react quickly and efficiently, and the measures to put in place so critical operations can continue.

In life science, and pharmacovigilance (PV), a continuity strategy is vital to ensure critical patient safety activities and global regulatory compliance continues. That’s because regulatory compliance activities that are mandated by global agencies including FDA, EMA and PMDA can be impacted by multiple factors ranging from cybercrime to natural disasters. Rethinking BCPs regularly is crucial to preparing for future disaster events.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader

IQVIA Integrated Global Compliance